TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneSelective use of sorafenib in the treatment of thyroid cancerTERT promoter mutations in thyroid cancerMutation Profile of Well-Differentiated Thyroid Cancer in AsiansTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaPersonalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsBRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.BRAF activates and physically interacts with PAK to regulate cell motility2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerIntegrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Neoplasia in Cri du Chat Syndrome from Italian and German Databases.A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinomaBRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's ThyroiditisAssociation of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from ChernobylAssociation of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid CarcinomaTERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patientsTelomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.A panel of four genes accurately differentiates benign from malignant thyroid nodules.TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysisActivation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
P2860
Q26738705-E1236798-28BE-4EF5-A67D-3D2A3892D939Q26739925-350521E4-2736-448F-A924-51D9F84B97D6Q26752891-9B2D22CC-AA1C-4570-AE1D-09155BA608BDQ26770808-10858FBF-C684-47ED-A12E-1C52E5E39998Q26782322-B2D1094E-75C8-42E5-B09F-411D9A5DC75EQ26853261-2D137906-1F8F-4BE5-8EC8-7A5E3371406DQ27027491-D7F078EB-9A56-4DB0-BE84-C1BC5BC7FEE3Q27853042-213A7CEA-EDF7-45B0-996B-3BBAD2778522Q27853057-2B1EB04F-1956-46AA-A19F-5ABBA4672C31Q28248127-92B69A06-1CE0-4EF2-A531-314DAF1DA584Q30367068-665F383E-1F10-402A-9E6B-F8234EB41847Q33629836-0828FECA-BB52-49BC-908D-C89746500C0FQ33646339-8538E196-045A-4C67-83C4-AE0E036F5105Q33656624-90A2CD17-6F8D-43AA-84D4-F42AEB5B0A88Q33875906-19F8F085-BD2C-4F2F-85F9-801FD65808F2Q33884794-F73BE0D6-A121-4394-84C2-71143FA95C94Q35441872-7E7B9CC1-EB79-4AD4-BDEA-DA48BC9E833AQ35554680-ADFADFAE-5FD5-43D3-8927-90A90A2AAC32Q35692478-58A85D43-7515-4637-906B-042F0855B4D7Q35857790-B7013426-63F5-4DBD-87A6-84EF94479706Q35901458-4C5C4BF4-8EAB-4A8B-BF43-EA6BEBA32407Q35985808-76D73E44-E623-4D55-8123-31DBE1876FBDQ36014228-1CD62D67-6B74-40FF-B21A-2D3EB48F3309Q36015168-3BF1363F-CC1C-4F60-B70A-672882A194E3Q36221232-C237833F-79A9-42E3-8E38-C45F62316E10Q36301491-46B0130F-11E7-4891-BD06-BADB6638CF97Q36339926-CD0E55F8-74D2-49FF-A03C-6B70AF9A27C4Q36431628-97019D07-4EC7-437C-B374-1E53F14BBC16Q36560914-AEA3124C-F11D-477E-B218-0881B573C7EBQ36716977-C77BDD7E-304C-48ED-BD3E-771E214A96DBQ37097535-F7E621EF-2518-4635-BDEB-94DEE57C144BQ37109755-80900207-43F6-4919-B88D-B6C086A9517EQ37317414-5D32F676-9BCA-46FA-A2FB-D51E978DC3EEQ37374678-4B019B86-3BBE-4910-BFD4-B8A14F2F82C1Q37408393-43BAC927-CC04-49C1-8C7D-39D0848FB6EBQ37514988-1A9C0907-DBFD-48B8-8335-3C4B7AAFDF58Q38383121-C9BBFC37-BD17-4E21-9B2F-988227FC7F05Q38416278-C9A3E661-903F-4D31-99DD-3A64359F13B5Q38614394-BCB7F667-1C84-446D-9DEF-A7C211F0CE55Q38687220-1F83659D-1A9B-4376-B813-81ACBBD54AC1
P2860
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@ast
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@en
type
label
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@ast
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@en
prefLabel
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@ast
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@en
P2093
P2860
P356
P1476
TERT promoter mutations and th ...... acteristics of thyroid cancer.
@en
P2093
Avaniyapuram Kannan Murugan
Chunjun Sheng
Guangwu Zhu
Haixia Guan
Mingzhao Xing
Rengyun Liu
Weiping Teng
P2860
P304
P356
10.1210/JC.2013-4048
P407
P577
2014-03-11T00:00:00Z